Who
John W. Smither
Director
Company insider
Files Form 4 as: Director, NewAmsterdam Pharma Company; Chief Financial Officer, MBX Biosciences; Director, Genelux; Chief Financial Officer, Arcutis Biotherapeutics; Director, Applied Molecular Transport; Director, eFFECTOR Therapeutics; Director, Principia Biopharma; Chief Financial Officer, Sienna Biopharmaceuticals.
In numbers
- Trades disclosed
- 212
- Buys
- 1
- Sells
- 42
- Bought
- $0
- Sold
- $8.8M
- Companies
- 10
- Companies where not an officer
- 6
- First trade
- 29 Jan 2013
- Last trade
- 4 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 9 Sep 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $41K1,600 at $25.32 | filing |
| 4 Sep 2026filed 9 Sep 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $41K1,600 at $25.32 | filing |
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $35K12,000 at $2.91 | filing |
| 1 Jul 2026filed 2 Jul 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $35K12,000 at $2.91 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —28,409 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,566 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,566 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —28,409 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —3,400 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —3,400 | filing |
| 27 Aug 2025filed 29 Aug 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,576 at $0.00 | filing |
| 27 Aug 2025filed 29 Aug 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —22,283 at $0.00 | filing |
| 7 Jan 2025filed 8 Jan 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —6,960 | filing |
| 6 Jan 2025filed 8 Jan 2025 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
News
Genelux (NASDAQ:GNLX) Upgraded at Wall Street ZenGNLX · dailypolitical.com · 23 Oct 2026Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)NAMS · dailypolitical.com · 14 Oct 2026Analyzing NewAmsterdam Pharma (NASDAQ:NAMS) & Grifols (NASDAQ:GRFS)NAMS · tickerreport.com · 14 Oct 2026Comparing Protagonist Therapeutics (NASDAQ:PTGX) and Genelux (NASDAQ:GNLX)GNLX · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name John W. Smither; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.